<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/viking-therapeutics-inc-logo-1200x675.png/query-dj0yMDI0MDMwNjEzMDYwNQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/viking-therapeutics-inc-logo-1200x675.png/query-dj0yMDI0MDMwNjEzMDYwNQ"/></p>
<p>維京治療（NASDAQ：VKTX - 獲取免費報告）的股票在週二的一份研究報告中被 HC Wainwright 的股票研究分析師重新確認為 “買入” 評級，據 Benzinga 報道。他們目前對這家生物技術公司的股票設定了 90.00 美元的價格目標。HC Wainwright 的價格目標顯示，相較於股票之前的收盤價，有 45.75% 的潛在上漲空間。</p>
<p>獲取 <strong>維京治療</strong> 的警報：</p>
<ul>
<li>艾利·莉莉（Eli Lilly）因 GLP-1 減重現象而上漲</li>
</ul>
<p>其他幾家股票研究分析公司最近也對該公司發表了評論。Stifel Nicolaus 在 3 月 15 日星期五的研究報告中重申了 “買入” 評級，並對維京治療的股票設定了 80.00 美元的目標價。Maxim Group 在 3 月 15 日星期五的研究報告中重申了 “買入” 評級，並對維京治療的股票設定了 120.00 美元的目標價。Truist Financial 在 5 月 16 日星期四的研究報告中重申了 “買入” 評級，並對維京治療的股票設定了 120.00 美元的價格目標。William Blair 在 2 月 23 日星期五的研究報告中重申了對維京治療的 “表現優異” 評級。最後，BTIG Research 將維京治療的價格目標從 100.00 美元上調至 125.00 美元，並在 3 月 26 日星期二的研究報告中給予該股票 “買入” 評級。一位股票研究分析師對該股票進行了賣出評級，八家公司給予了買入評級，一家公司給予了強烈買入評級。根據 MarketBeat 的數據，維京治療目前的共識評級為 “中度買入”，平均目標價為 112.38 美元。</p>
<p>獲取我們關於維京治療的最新報告</p>
<h2>維京治療股票下跌 0.8%</h2>
<ul>
<li>Wegovy vs. Zepbound：GLP-1 藥物之戰誰將獲勝？</li>
</ul>
<p>週二，納斯達克：VKTX 的股票下跌了 0.52 美元，收於 61.75 美元。該公司的股票交易量為 1,115,532 股，相比其平均交易量 4,970,656 股有所下降。該公司的市值為 68.1 億美元，市盈率為-67.17，貝塔係數為 1.05。該公司的 50 天移動平均價格為 71.44 美元，200 天移動平均價格為 46.58 美元。維京治療的 52 周最低價為 8.28 美元，最高價為 99.41 美元。</p>
<p>維京治療（NASDAQ：VKTX - 獲取免費報告）上次發佈財報是在 4 月 24 日星期三。這家生物技術公司報告的每股收益為（0.26）美元，超過了每股（0.27）美元的共識預期。在去年同期，該公司每股收益為（0.25）美元。分析師平均預測，維京治療在本財年將實現-1.08 美元的每股收益。</p>
<h2>維京治療內部交易</h2>
<ul>
<li>Altimmune 能否在現金流耗盡之前將其 GLP-1 藥物推向市場？</li>
</ul>
<p>在其他維京治療的消息中，首席財務官 Greg Zante 於 5 月 3 日星期五以每股 74.69 美元的均價出售了 66,756 股公司股票。該交易總價值為 4,986,005.64 美元。交易完成後，首席財務官現在直接持有公司股票 174,854 股，價值約 13,059,845.26 美元。該交易已在向 SEC 提交的法律文件中披露，可通過此鏈接訪問。此外，首席運營官 Marianna Mancini 於 5 月 1 日星期三以每股 78.66 美元的均價出售了 281,425 股股票。該股票的總交易額為 22,136,890.50 美元。交易完成後，首席運營官現在直接持有公司股票 348,508 股，價值約 27,413,639.28 美元。該交易已在向 SEC 提交的法律文件中披露，可通過 SEC 網站訪問。此外，首席財務官 Greg Zante 於 5 月 3 日星期五以每股 74.69 美元的均價出售了 66,756 股公司股票。該交易總價值為 4,986,005.64 美元。交易完成後，首席財務官持有公司股票 174,854 股，價值 13,059,845.26 美元。有關此次交易的披露可在此處找到。內部持有公司股票的比例為公司股份的 4.70%。</p>
<h2>維京治療的機構交易</h2>
<p>機構投資者和對沖基金最近調整了他們對該公司的持股。Rafferty Asset Management LLC 在第 3 季度將其在維京治療的持股增加了 63.6%。Rafferty Asset Management LLC 現在擁有 560,180 股這家生物技術公司的股票，價值 6,201,000 美元，比上一季度增加了 217,827 股。International Assets Investment Management LLC 在第 4 季度將其在維京治療的持股增加了 1,557.6%。International Assets Investment Management LLC 現在擁有 371,604 股這家生物技術公司的股票，價值 6,916,000 美元，比上一季度增加了 349,186 股。Raymond James &amp; Associates 在第 4 季度將其在維京治療的持股增加了 100.4%。Raymond James &amp; Associates 現在擁有 137,583 股這家生物技術公司的股票，價值 2,560,000 美元，比上一季度增加了 68,921 股。Vanguard Group Inc.在第 3 季度將其在維京治療的持股增加了 3.4%。Vanguard Group Inc.現在擁有 5,284,352 股這家生物技術公司的股票，價值 58,498,000 美元，比上一季度增加了 171,995 股。最後，Aigen Investment Management LP 在第 3 季度購入了維京治療的股份，價值 148,000 美元。目前，公司股份的 76.03% 由機構投資者持有。</p>
<h2>關於維京治療（獲取免費報告）</h2>
<p>Viking 治療公司是一家臨牀階段的生物製藥公司，專注於開發治療代謝和內分泌疾病的新型療法。該公司的主力藥物候選是 VK2809，一種口服可用的組織和受體亞型選擇性激動劑，作用於甲狀腺激素受體β（TRß），目前正在進行 IIb 期臨牀試驗，用於治療經活檢確認的非酒精性脂肪肝病患者，以及 NAFLD。</p>
<h2>精選故事</h2>
<ul>
<li>五隻我們比 Viking 治療更喜歡的股票</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>Birkenstock 看起來適合任何成長型投資組合</li>
<li>什麼是富時 100 指數？</li>
<li>本季度最活躍的國會交易</li>
<li>期權交易 - 瞭解行權價</li>
<li>C3.ai 開始展現人工智能助推力加速</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA"/></p>
<p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
<p>→ 特別免費提供股票熱表（來自 DTI）（廣告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MTY0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MTY0"/></p>
<h2>現在是否值得投資 1,000 美元購買 Viking 治療股票？</h2>
<p>在考慮購買 Viking 治療股票之前，您需要聽到這個消息。</p>
<p>MarketBeat 追蹤華爾街頂尖和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂尖分析師悄悄告訴客户現在購買的股票，讓更廣泛的市場注意到...而 Viking 治療並不在名單上。</p>
<p>儘管 Viking 治療目前在分析師中有 “買入” 評級，但頂尖分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Viking治療

<p>維京治療（NASDAQ:VKTX）收到了 HC Wainwright 的 “買入” 評級，目標股價為 90.00 美元。其他分析師也對這家生物技術公司給予了積極評價。維京治療的 52 周最低股價為 8.28 美元，52 周最高股價為 99.41 美元。該公司的股票在上一個交易日收盤價為 61.75 美元，市值為 68.1 億美元。內部人士一直在拋售該公司的股份</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/logos/viking-therapeutics-inc-logo-1200x675.png/query-dj0yMDI0MDMwNjEzMDYwNQ" alt="" original-src="https://www.marketbeat.com/logos/viking-therapeutics-inc-logo-1200x675.png?v=20240306130605"/></p>
<p>Viking Therapeutics (NASDAQ:VKTX - Get Free Report)'s stock had its &#34;buy&#34; rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $90.00 price objective on the biotechnology company's stock. HC Wainwright's price objective indicates a potential upside of 45.75% from the stock's previous close.</p>
<div class="lb-trans"><p>維京治療（NASDAQ：VKTX - 獲取免費報告）的股票在週二的一份研究報告中被 HC Wainwright 的股票研究分析師重新確認為 “買入” 評級，據 Benzinga 報道。他們目前對這家生物技術公司的股票設定了 90.00 美元的價格目標。HC Wainwright 的價格目標顯示，相較於股票之前的收盤價，有 45.75% 的潛在上漲空間。</p>
</div><p>Get <strong>Viking Therapeutics</strong> alerts:</p>
<ul>
<li>Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon</li>
</ul>
<div class="lb-trans"><p>獲取 <strong>維京治療</strong> 的警報：</p>
<ul>
<li>艾利·莉莉（Eli Lilly）因 GLP-1 減重現象而上漲</li>
</ul>
</div><p>Several other equities research analysts have also recently commented on the company. Stifel Nicolaus restated a &#34;buy&#34; rating and issued a $80.00 target price on shares of Viking Therapeutics in a research note on Friday, March 15th. Maxim Group restated a &#34;buy&#34; rating and issued a $120.00 target price on shares of Viking Therapeutics in a research note on Friday, March 15th. Truist Financial reiterated a &#34;buy&#34; rating and set a $120.00 price objective on shares of Viking Therapeutics in a research note on Thursday, May 16th. William Blair reiterated an &#34;outperform&#34; rating on shares of Viking Therapeutics in a research note on Friday, February 23rd. Finally, BTIG Research upped their price objective on Viking Therapeutics from $100.00 to $125.00 and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, March 26th. One equities research analyst has rated the stock with a sell rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Viking Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $112.38.</p>
<div class="lb-trans"><p>其他幾家股票研究分析公司最近也對該公司發表了評論。Stifel Nicolaus 在 3 月 15 日星期五的研究報告中重申了 “買入” 評級，並對維京治療的股票設定了 80.00 美元的目標價。Maxim Group 在 3 月 15 日星期五的研究報告中重申了 “買入” 評級，並對維京治療的股票設定了 120.00 美元的目標價。Truist Financial 在 5 月 16 日星期四的研究報告中重申了 “買入” 評級，並對維京治療的股票設定了 120.00 美元的價格目標。William Blair 在 2 月 23 日星期五的研究報告中重申了對維京治療的 “表現優異” 評級。最後，BTIG Research 將維京治療的價格目標從 100.00 美元上調至 125.00 美元，並在 3 月 26 日星期二的研究報告中給予該股票 “買入” 評級。一位股票研究分析師對該股票進行了賣出評級，八家公司給予了買入評級，一家公司給予了強烈買入評級。根據 MarketBeat 的數據，維京治療目前的共識評級為 “中度買入”，平均目標價為 112.38 美元。</p>
</div><p><strong>Get Our Latest Report on Viking Therapeutics</strong></p>
<div class="lb-trans"><p>獲取我們關於維京治療的最新報告</p>
</div><h2>Viking Therapeutics Trading Down 0.8 %</h2>
<ul>
<li>Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?</li>
</ul>
<div class="lb-trans"><h2>維京治療股票下跌 0.8%</h2>
<ul>
<li>Wegovy vs. Zepbound：GLP-1 藥物之戰誰將獲勝？</li>
</ul>
</div><p>Shares of NASDAQ:VKTX traded down $0.52 during trading on Tuesday, hitting $61.75. 1,115,532 shares of the company's stock traded hands, compared to its average volume of 4,970,656. The company has a market cap of $6.81 billion, a price-to-earnings ratio of -67.17 and a beta of 1.05. The company has a 50-day moving average price of $71.44 and a 200-day moving average price of $46.58. Viking Therapeutics has a 52 week low of $8.28 and a 52 week high of $99.41.</p>
<div class="lb-trans"><p>週二，納斯達克：VKTX 的股票下跌了 0.52 美元，收於 61.75 美元。該公司的股票交易量為 1,115,532 股，相比其平均交易量 4,970,656 股有所下降。該公司的市值為 68.1 億美元，市盈率為-67.17，貝塔係數為 1.05。該公司的 50 天移動平均價格為 71.44 美元，200 天移動平均價格為 46.58 美元。維京治療的 52 周最低價為 8.28 美元，最高價為 99.41 美元。</p>
</div><p>Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its earnings results on Wednesday, April 24th. The biotechnology company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.01. During the same period in the prior year, the firm posted ($0.25) earnings per share. On average, analysts predict that Viking Therapeutics will post -1.08 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>維京治療（NASDAQ：VKTX - 獲取免費報告）上次發佈財報是在 4 月 24 日星期三。這家生物技術公司報告的每股收益為（0.26）美元，超過了每股（0.27）美元的共識預期。在去年同期，該公司每股收益為（0.25）美元。分析師平均預測，維京治療在本財年將實現-1.08 美元的每股收益。</p>
</div><h2>Insider Buying and Selling at Viking Therapeutics</h2>
<ul>
<li>Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?</li>
</ul>
<div class="lb-trans"><h2>維京治療內部交易</h2>
<ul>
<li>Altimmune 能否在現金流耗盡之前將其 GLP-1 藥物推向市場？</li>
</ul>
</div><p>In other Viking Therapeutics news, CFO Greg Zante sold 66,756 shares of the company's stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $74.69, for a total value of $4,986,005.64. Following the transaction, the chief financial officer now directly owns 174,854 shares of the company's stock, valued at approximately $13,059,845.26. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, COO Marianna Mancini sold 281,425 shares of the stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $78.66, for a total transaction of $22,136,890.50. Following the sale, the chief operating officer now directly owns 348,508 shares of the company's stock, valued at approximately $27,413,639.28. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CFO Greg Zante sold 66,756 shares of the company's stock in a transaction on Friday, May 3rd. The stock was sold at an average price of $74.69, for a total value of $4,986,005.64. Following the sale, the chief financial officer now owns 174,854 shares of the company's stock, valued at $13,059,845.26. The disclosure for this sale can be found here. Insiders own 4.70% of the company's stock.</p>
<div class="lb-trans"><p>在其他維京治療的消息中，首席財務官 Greg Zante 於 5 月 3 日星期五以每股 74.69 美元的均價出售了 66,756 股公司股票。該交易總價值為 4,986,005.64 美元。交易完成後，首席財務官現在直接持有公司股票 174,854 股，價值約 13,059,845.26 美元。該交易已在向 SEC 提交的法律文件中披露，可通過此鏈接訪問。此外，首席運營官 Marianna Mancini 於 5 月 1 日星期三以每股 78.66 美元的均價出售了 281,425 股股票。該股票的總交易額為 22,136,890.50 美元。交易完成後，首席運營官現在直接持有公司股票 348,508 股，價值約 27,413,639.28 美元。該交易已在向 SEC 提交的法律文件中披露，可通過 SEC 網站訪問。此外，首席財務官 Greg Zante 於 5 月 3 日星期五以每股 74.69 美元的均價出售了 66,756 股公司股票。該交易總價值為 4,986,005.64 美元。交易完成後，首席財務官持有公司股票 174,854 股，價值 13,059,845.26 美元。有關此次交易的披露可在此處找到。內部持有公司股票的比例為公司股份的 4.70%。</p>
</div><h2>Institutional Trading of Viking Therapeutics</h2>
<div class="lb-trans"><h2>維京治療的機構交易</h2>
</div><p>Institutional investors and hedge funds have recently modified their holdings of the business. Rafferty Asset Management LLC lifted its position in shares of Viking Therapeutics by 63.6% during the 3rd quarter. Rafferty Asset Management LLC now owns 560,180 shares of the biotechnology company's stock worth $6,201,000 after buying an additional 217,827 shares during the last quarter. International Assets Investment Management LLC lifted its position in shares of Viking Therapeutics by 1,557.6% during the 4th quarter. International Assets Investment Management LLC now owns 371,604 shares of the biotechnology company's stock worth $6,916,000 after buying an additional 349,186 shares during the last quarter. Raymond James &amp; Associates lifted its position in shares of Viking Therapeutics by 100.4% during the 4th quarter. Raymond James &amp; Associates now owns 137,583 shares of the biotechnology company's stock worth $2,560,000 after buying an additional 68,921 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Viking Therapeutics by 3.4% during the 3rd quarter. Vanguard Group Inc. now owns 5,284,352 shares of the biotechnology company's stock worth $58,498,000 after buying an additional 171,995 shares during the last quarter. Finally, Aigen Investment Management LP bought a new stake in shares of Viking Therapeutics during the 3rd quarter worth $148,000. 76.03% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>機構投資者和對沖基金最近調整了他們對該公司的持股。Rafferty Asset Management LLC 在第 3 季度將其在維京治療的持股增加了 63.6%。Rafferty Asset Management LLC 現在擁有 560,180 股這家生物技術公司的股票，價值 6,201,000 美元，比上一季度增加了 217,827 股。International Assets Investment Management LLC 在第 4 季度將其在維京治療的持股增加了 1,557.6%。International Assets Investment Management LLC 現在擁有 371,604 股這家生物技術公司的股票，價值 6,916,000 美元，比上一季度增加了 349,186 股。Raymond James &amp; Associates 在第 4 季度將其在維京治療的持股增加了 100.4%。Raymond James &amp; Associates 現在擁有 137,583 股這家生物技術公司的股票，價值 2,560,000 美元，比上一季度增加了 68,921 股。Vanguard Group Inc.在第 3 季度將其在維京治療的持股增加了 3.4%。Vanguard Group Inc.現在擁有 5,284,352 股這家生物技術公司的股票，價值 58,498,000 美元，比上一季度增加了 171,995 股。最後，Aigen Investment Management LP 在第 3 季度購入了維京治療的股份，價值 148,000 美元。目前，公司股份的 76.03% 由機構投資者持有。</p>
</div><h2>About Viking Therapeutics (Get Free Report)</h2>
<div class="lb-trans"><h2>關於維京治療（獲取免費報告）</h2>
</div><p>Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.</p>
<div class="lb-trans"><p>Viking 治療公司是一家臨牀階段的生物製藥公司，專注於開發治療代謝和內分泌疾病的新型療法。該公司的主力藥物候選是 VK2809，一種口服可用的組織和受體亞型選擇性激動劑，作用於甲狀腺激素受體β（TRß），目前正在進行 IIb 期臨牀試驗，用於治療經活檢確認的非酒精性脂肪肝病患者，以及 NAFLD。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than Viking Therapeutics</li>
<li>What Are Dividends? Buy the Best Dividend Stocks</li>
<li>Birkenstock Looks Like a Fit in Any Growth-Oriented Portfolio</li>
<li>What is the FTSE 100 index?</li>
<li>These Are the Most Active Congressional Trades This Quarter</li>
<li>Options Trading - Understanding Strike Price</li>
<li>C3.ai is Starting to Show AI Tailwinds Accelerating</li>
</ul>
<div class="lb-trans"><h2>精選故事</h2>
<ul>
<li>五隻我們比 Viking 治療更喜歡的股票</li>
<li>什麼是股息？購買最佳股息股票</li>
<li>Birkenstock 看起來適合任何成長型投資組合</li>
<li>什麼是富時 100 指數？</li>
<li>本季度最活躍的國會交易</li>
<li>期權交易 - 瞭解行權價</li>
<li>C3.ai 開始展現人工智能助推力加速</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VktUWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=VKTX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>這則即時新聞警報是由 MarketBeat 的敍事科技和金融數據生成，旨在為讀者提供最快速和最準確的報道。本故事在發佈前經過 MarketBeat 編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><p>→ Special FREE offer on stock hotsheets (From DTI)(Ad)</p>
<div class="lb-trans"><p>→ 特別免費提供股票熱表（來自 DTI）（廣告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04MTY0" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8164&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Viking Therapeutics right now?</h2>
<div class="lb-trans"><h2>現在是否值得投資 1,000 美元購買 Viking 治療股票？</h2>
</div><p>Before you consider Viking Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮購買 Viking 治療股票之前，您需要聽到這個消息。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追蹤華爾街頂尖和表現最佳的研究分析師以及他們每天向客户推薦的股票。MarketBeat 已經確定了五隻頂尖分析師悄悄告訴客户現在購買的股票，讓更廣泛的市場注意到...而 Viking 治療並不在名單上。</p>
</div><p>While Viking Therapeutics currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>儘管 Viking 治療目前在分析師中有 “買入” 評級，但頂尖分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Viking 治療（NASDAQ 代碼：VKTX）獲得 HC Wainwright 的 “買入” 評級